Wang, Yi
Wang, Wenchao
Yu, Endian
Zhuang, Wenya
Sun, Xuanrong
Wang, Hong
Li, Qingyong
Funding for this research was provided by:
Key Research and Development Program of Zhejiang (2021C03084, 2021C03084, 2021C03084, 2021C03084, 2021C03084, 2021C03084, 2021C03084)
National Natural Science Foundation of China (No. 31270397, No. 31270397, No. 31270397, No. 31270397, No. 31270397, No. 31270397, No. 31270397)
High-Level Talent Special Support Plan of Zhejiang Province (2019R52009, 2019R52009, 2019R52009, 2019R52009, 2019R52009, 2019R52009, 2019R52009)
Article History
Received: 12 April 2022
Accepted: 31 July 2022
First Online: 5 September 2022
Declarations
:
: All experimental procedures involving animals performed in this study were previously approved and certified (No. 20201012126) by the animal experiment center of Zhejiang University of Technology, which strictly complies with the PR China legislation for the use and care of laboratory animals.
: Not applicable.
: FLQY2-SD will be further developed at Zhejiang University of Technology for the treatment of cancer.